Article Information
History
- June 15, 2020.
Article Versions
- Version 1 (June 13, 2020 - 16:57).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lydia J Finney1,
- Nicholas Glanville2,
- Hugo Farne1,
- Julia Aniscenko1,
- Peter Fenwick1,
- Samuel V Kemp1,3,
- Maria-Belen Trujillo-Torralbo1,
- Maria Adelaide Calderazzo1,
- Jadwiga A Wedzicha1,
- Patrick Mallia1,
- Nathan W Bartlett4,
- Sebastian L Johnston1 and
- Aran Singanayagam1,#
- 1National Heart and Lung Institute, Imperial College London
- 2Prokarium, London BioScience Innovation Centre, 2 Royal College Street, London NW1 0NH
- 3Royal Brompton and Harefield NHS Trust
- 4Faculty of Health and Medicine and Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and University of Newcastle
- ↵#Corresponding author: Dr Aran Singanayagam PhD. MRCP. National Heart and Lung Institute Imperial College London W2 1PG a.singanayagam{at}imperial.ac.uk
Posted June 15, 2020.
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
